|
COPYRIGHT 2004 International Medical News Group
BUDAPEST, HUNGARY -- After many years of use in Germany, fumaric acid esters are now emerging onto the broader international dermatologic stage as a potential systemic therapy for severe psoriasis.
In a double-blind, placebo-controlled phase II study conducted at four centers in Poland, statistically significant, rapid improvements were seen in Psoriasis Area and Severity index (PASI) scores in a group of 144 patients with the chronic plaque, exanthematic guttate, erythrodermic, palmoplantar, or pustular types of psoriasis, Dr. A. Langner reported at an international symposium sponsored by the European Academy of Dermatology and Venereology.
Patients were required...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
